世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000038047

炎症性腸疾患(IBD)治療薬市場レポート2024-2034

Visiongain

Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

発刊日 2024/04/11

言語英語

体裁PDF/318ページ

ライセンス/価格318ページ

0000038047

Single - 1 Year License
(Team License - Up to 6 Users) - 1 Year License
Site
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※シングルユーザーライセンスのレポートは印刷不可、およびライセンス期間は1年となります。
※印刷可能のレポートをご希望の場合は、デパートメントライセンス(ライセンス期間1年、ユーザー数6人)をご検討ください。
※詳しくはお問い合わせください。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

適応症別 (クローン病、潰瘍性大腸炎)、投与経路別 (経口、非経口、直腸)、流通チャネル別 (病院薬局、小売薬局、Eコマース薬局、その他)、薬剤クラス別 (TNF-α遮断薬、インテグリン遮断薬、インターロイキン阻害剤、JAK阻害剤、S1Psモジュレーター、その他)、薬剤別 (Cimzia、Entyvio、Humira、Rinvoq、Skyrizi、Remicade、Simponi、Stelara、その他)、地域別および主要な国内市場分析と主要な分析企業とCOVID-19の影響と回復パターン分析

IBD治療薬市場の需要を後押しするIBD発生率の上昇

炎症性腸疾患(IBD)の世界的な発生率と有病率は増加しており、先進国と発展途上国の間で顕著な違いがあります。クローン病と潰瘍性大腸炎は先進国でより一般的であり、西洋の食事やライフスタイルの要因が原因である可能性があります。急速な都市化が、IBDを含む自己免疫疾患の増加にも貢献しています。欧米では発生率は安定しているように見えますが、おそらく西洋化と疾病意識の向上により、発展途上国では増加しています。最近の研究では、特に以前は発生率が低かった地域で発生率が上昇していることが示されています。ヨーロッパの発生率が最も高く、北米、アジア/中東がそれに続きます。EFCCA (欧州クローン病・潰瘍性大腸炎協会連合会) によると、2022年には世界で1,000万人がIBDに罹患しています。CCFA (Crohn's & Colitis Foundation of America)によると、米国では毎年70,000人ものIBDが新たに診断されており、米国では約80,000人の子供がIBDに罹患していると推定されています。IBDは、約160万人のアメリカ人が罹患していると報告されており、そのほとんどが35歳未満で診断されています。

レポート詳細

目次

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Inflammatory Bowel Diseases Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Rise in IBD Incidence to Boost the Demand of IBD Drugs Market
3.2.1.2 Significant success in IBD Drug Development to Drive the Market Demand
3.2.1.3 Advancements in Oral Drug Delivery for Inflammatory Bowel Disease
3.2.2 Market Restraining Factors
3.2.2.1 Lack of Understanding of Disease Aetiology
3.2.2.2 Compliance - Frequent Dosing is Inconvenient
3.2.2.3 Limitations of IBD Drugs - Side Effect Profiles
3.2.3 Market Opportunities
3.2.3.1 Advancements in Biological Drugs to Drive the Market Significantly
3.2.3.2 Rising Opportunities for IBD Drugs in Asian Markets
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis

4 Inflammatory Bowel Diseases Drugs Market Analysis by Indication
4.1 Key Findings
4.2 Indication Segment: Market Attractiveness Index
4.3 Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Indication
4.4 Crohn’s Disease
4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Ulcerative Colitis
4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.5.2 Market Share by Region, 2024 & 2034 (%)

5 Inflammatory Bowel Diseases Drugs Market Analysis by Route of Administration
5.1 Key Findings
5.2 Indication Segment: Market Attractiveness Index
5.3 Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Route of Administration
5.4 Oral
5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Parenteral
5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Rectal
5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
5.6.2 Market Share by Region, 2024 & 2034 (%)

6 Inflammatory Bowel Diseases Drugs Market Analysis by Distribution Channel
6.1 Key Findings
6.2 Indication Segment: Market Attractiveness Index
6.3 Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Distribution Channel
6.4 Hospital Pharmacy
6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Retail Pharmacy
6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 E-commerce Pharmacy
6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
6.6.2 Market Share by Region, 2024 & 2034 (%)
6.7 Others
6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
6.7.2 Market Share by Region, 2024 & 2034 (%)

7 Inflammatory Bowel Diseases Drugs Market Analysis by Drug Class
7.1 Key Findings
7.2 Drug Class Segment: Market Attractiveness Index
7.3 Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drug Class
7.4 TNF-alpha Blockers
7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Integrin Blockers
7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Interleukin Inhibitors
7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
7.6.2 Market Share by Region, 2024 & 2034 (%)
7.7 JAK inhibitors
7.7.1 Market Size by Region, 2024-2034 (US$ Billion)
7.7.2 Market Share by Region, 2024 & 2034 (%)
7.8 S1Ps Modulators and Others
7.8.1 Market Size by Region, 2024-2034 (US$ Billion)
7.8.2 Market Share by Region, 2024 & 2034 (%)

8 Inflammatory Bowel Diseases Drugs Market Analysis by Drugs
8.1 Key Findings
8.2 Drugs Segment: Market Attractiveness Index
8.3 Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drugs
8.4 Cimzia
8.4.1 Market Size by Region, 2024-2034 (US$ Billion)
8.4.2 Market Share by Region, 2024 & 2034 (%)
8.5 Entyvio
8.5.1 Market Size by Region, 2024-2034 (US$ Billion)
8.5.2 Market Share by Region, 2024 & 2034 (%)
8.6 Humira
8.6.1 Market Size by Region, 2024-2034 (US$ Billion)
8.6.2 Market Share by Region, 2024 & 2034 (%)
8.7 Rinvoq
8.7.1 Market Size by Region, 2024-2034 (US$ Billion)
8.7.2 Market Share by Region, 2024 & 2034 (%)
8.8 Skyrizi
8.8.1 Market Size by Region, 2024-2034 (US$ Billion)
8.8.2 Market Share by Region, 2024 & 2034 (%)
8.9 Remicade
8.9.1 Market Size by Region, 2024-2034 (US$ Billion)
8.9.2 Market Share by Region, 2024 & 2034 (%)
8.10 Simponi
8.10.1 Market Size by Region, 2024-2034 (US$ Billion)
8.10.2 Market Share by Region, 2024 & 2034 (%)
8.11 Stelara
8.11.1 Market Size by Region, 2024-2034 (US$ Billion)
8.11.2 Market Share by Region, 2024 & 2034 (%)
8.12 Others
8.12.1 Market Size by Region, 2024-2034 (US$ Billion)
8.12.2 Market Share by Region, 2024 & 2034 (%)

9 Inflammatory Bowel Diseases Drugs Market Analysis by Region
9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast

10 North America Inflammatory Bowel Diseases Drugs Market Analysis
10.1 Key Findings
10.2 North America Inflammatory Bowel Diseases Drugs Market Attractiveness Index
10.3 North America Inflammatory Bowel Diseases Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
10.4 North America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Country
10.5 North America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Indication
10.6 North America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Route of Administration
10.7 North America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Distribution Channel
10.8 North America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drug Class
10.9 North America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drugs
10.10 U.S. Inflammatory Bowel Diseases Drugs Market Analysis
10.11 Canada Inflammatory Bowel Diseases Drugs Market Analysis

11 Europe Inflammatory Bowel Diseases Drugs Market Analysis
11.1 Key Findings
11.2 Europe Inflammatory Bowel Diseases Drugs Market Attractiveness Index
11.3 Europe Inflammatory Bowel Diseases Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
11.4 Europe Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Country
11.5 Europe Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Indication
11.6 Europe Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Route of Administration
11.7 Europe Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Distribution Channel
11.8 Europe Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drug Class
11.9 Europe Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drugs
11.10 Germany Inflammatory Bowel Diseases Drugs Market Analysis
11.11 France Inflammatory Bowel Diseases Drugs Market Analysis
11.12 UK Inflammatory Bowel Diseases Drugs Market Analysis
11.13 Italy Inflammatory Bowel Diseases Drugs Market Analysis
11.14 Spain Inflammatory Bowel Diseases Drugs Market Analysis
11.15 Rest of Europe Inflammatory Bowel Diseases Drugs Market Analysis

12 Asia Pacific Inflammatory Bowel Diseases Drugs Market Analysis
12.1 Key Findings
12.2 Asia Pacific Inflammatory Bowel Diseases Drugs Market Attractiveness Index
12.3 Asia Pacific Inflammatory Bowel Diseases Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
12.4 Asia Pacific Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Country
12.5 Asia Pacific Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Indication
12.6 Asia Pacific Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Route of Administration
12.7 Asia Pacific Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Distribution Channel
12.8 Asia Pacific Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drug Class
12.9 Asia Pacific Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drugs
12.10 Japan Inflammatory Bowel Diseases Drugs Market Analysis
12.11 China Inflammatory Bowel Diseases Drugs Market Analysis
12.12 India Inflammatory Bowel Diseases Drugs Market Analysis
12.13 Australia Inflammatory Bowel Diseases Drugs Market Analysis
12.14 South Korea Inflammatory Bowel Diseases Drugs Market Analysis
12.15 Rest of Asia Pacific Inflammatory Bowel Diseases Drugs Market Analysis

13 Latin America Inflammatory Bowel Diseases Drugs Market Analysis
13.1 Key Findings
13.2 Latin America Inflammatory Bowel Diseases Drugs Market Attractiveness Index
13.3 Latin America Inflammatory Bowel Diseases Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
13.4 Latin America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Country
13.5 Latin America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Indication
13.6 Latin America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Route of Administration
13.7 Latin America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Distribution Channel
13.8 Latin America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drug Class
13.9 Latin America Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drugs
13.10 Brazil Inflammatory Bowel Diseases Drugs Market Analysis
13.11 Mexico Inflammatory Bowel Diseases Drugs Market Analysis
13.12 Rest of Latin America Inflammatory Bowel Diseases Drugs Market Analysis

14 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Analysis
14.1 Key Findings
14.2 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Attractiveness Index
14.3 Middle East and Africa Inflammatory Bowel Diseases Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
14.4 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Country
14.5 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Indication
14.6 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Route of Administration
14.7 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Distribution Channel
14.8 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drug Class
14.9 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Size Estimation and Forecast by Drugs
14.10 GCC Inflammatory Bowel Diseases Drugs Market Analysis
14.11 South Africa Inflammatory Bowel Diseases Drugs Market Analysis
14.12 Rest of MEA Inflammatory Bowel Diseases Drugs Market Analysis

15 Company Profiles
15.1 Competitive Landscape, 2023
15.2 Strategic Outlook
15.3 AbbVie
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2018-2022
15.3.3.2 R&D, 2018-2022
15.3.3.3 Regional Market Shares, 2022
15.3.4 Product Benchmarking
15.3.5 Strategic Outlook
15.4 Johnsons & Johnsons
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2018-2022
15.4.3.2 Regional Market Shares, 2022
15.4.4 Product Benchmarking
15.4.5 Strategic Outlook
15.5 Takeda Pharmaceutical Company Limited
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2019-2023
15.5.3.2 R&D, 2019-2023
15.5.3.3 Regional Market Shares, 2022
15.5.4 Product Benchmarking
15.5.5 Strategic Outlook
15.6 Pfizer
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.3.1 Net Revenue, 2018-2022
15.6.3.2 R&D, 2018-2022
15.6.3.3 Regional Market Shares, 2022
15.6.4 Product Benchmarking
15.6.5 Strategic Outlook
15.7 Novartis AG
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2018-2022
15.7.3.2 R&D, 2018-2022
15.7.3.3 Regional Market Shares, 2022
15.7.4 Product Benchmarking
15.7.5 Strategic Outlook
15.8 UCB S.A.
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.3.1 Net Revenue, 2019-2023
15.8.3.2 R&D, 2019-2023
15.8.3.3 Regional Market Shares, 2023
15.8.4 Product Benchmarking
15.8.5 Strategic Outlook
15.9 Biogen
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Financial Analysis
15.9.3.1 Net Revenue, 2019-2023
15.9.3.2 R&D, 2019-2023
15.9.4 Product Benchmarking
15.9.5 Strategic Outlook
15.10 F. Hoffmann-La Roche Ltd
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2018-2022
15.10.3.2 R&D, 2018-2022
15.10.4 Product Benchmarking
15.11 Celltrion Corporation
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Financial Analysis
15.11.3.1 Net Revenue, 2018-2022
15.11.3.2 R&D, 2018-2022
15.11.4 Product Benchmarking
15.11.5 Strategic Outlook
15.12 Ferring B.V.
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Product Benchmarking
15.12.4 Strategic Outlook

16 Conclusion and Recommendations
16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players

List of Tables
Table 1 Inflammatory Bowel Diseases Drugs Market Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
Table 2 Inflammatory Bowel Diseases Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “V” Shaped Recovery
Table 3 Inflammatory Bowel Diseases Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “U” Shaped Recovery
Table 4 Inflammatory Bowel Diseases Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “W” Shaped Recovery
Table 5 Inflammatory Bowel Diseases Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “L” Shaped Recovery
Table 6 Inflammatory Bowel Diseases Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 7 Crohn’s Disease Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR %)
Table 8 Ulcerative Colitis Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 9 Inflammatory Bowel Diseases Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 10 Oral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 11 Parenteral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 12 Rectal Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 13 Inflammatory Bowel Diseases Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 14 Hospital Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 15 Retail Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 16 E-commerce Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 17 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 18 Inflammatory Bowel Diseases Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 19 TNF-alpha Blockers Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 20 Integrin Blockers Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 21 Interleukin Inhibitors Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 22 JAK inhibitors Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 23 S1Ps Modulators and Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 24 Inflammatory Bowel Diseases Drugs Market Forecast by Drugs, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 25 Cimzia Blockers Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 26 Entyvio Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 27 Humira Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 28 Rinvoq Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 29 Skyrizi Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 30 Remicade Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 31 Simponi Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 32 Stelara Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 33 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 34 Inflammatory Bowel Diseases Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 35 North America Inflammatory Bowel Diseases Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 36 North America Inflammatory Bowel Diseases Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 37 North America Inflammatory Bowel Diseases Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 38 North America Inflammatory Bowel Diseases Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 39 North America Inflammatory Bowel Diseases Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 40 North America Inflammatory Bowel Diseases Drugs Market Forecast by Drugs, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 41 U.S. Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 42 Canada Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 43 Europe Inflammatory Bowel Diseases Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 44 Europe Inflammatory Bowel Diseases Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 45 Europe Inflammatory Bowel Diseases Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 46 Europe Inflammatory Bowel Diseases Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 47 Europe Inflammatory Bowel Diseases Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 48 Europe Inflammatory Bowel Diseases Drugs Market Forecast by Drugs, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 49 Germany Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 50 France Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 51 UK Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 52 Italy Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 53 Spain Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 54 Rest of Europe Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 55 Asia Pacific Vaccine Contract Manufacturing Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 56 Asia Pacific Inflammatory Bowel Diseases Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 57 Asia Pacific Inflammatory Bowel Diseases Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 58 Asia Pacific Inflammatory Bowel Diseases Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 59 Asia Pacific Inflammatory Bowel Diseases Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 60 Asia Pacific Inflammatory Bowel Diseases Drugs Market Forecast by Drugs, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 61 Japan Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 62 China Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 63 India Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 64 Australia Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 65 South Korea Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 66 Rest of Asia Pacific Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 67 Latin America Inflammatory Bowel Diseases Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 68 Latin America Inflammatory Bowel Diseases Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 69 Latin America Inflammatory Bowel Diseases Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 70 Latin America Inflammatory Bowel Diseases Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 71 Latin America Inflammatory Bowel Diseases Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 72 Latin America Inflammatory Bowel Diseases Drugs Market Forecast by Drugs, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 73 Brazil Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 74 Mexico Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 75 Rest of Latin America Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 76 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 77 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 78 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 79 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 80 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 81 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Forecast by Drugs, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 82 GCC Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 83 South Africa Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 84 Rest of MEA Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 85 Strategic Outlook
Table 86 AbbVie: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 AbbVie: Product Benchmarking
Table 88 AbbVie: Strategic Outlook
Table 89 Johnsons & Johnsons: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Johnsons & Johnsons: Product Benchmarking
Table 91 Johnsons & Johnsons: Strategic Outlook
Table 92 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Takeda Pharmaceutical Company Limited: Product Benchmarking
Table 94 Takeda Pharmaceutical Company Limited: Strategic Outlook
Table 95 Pfizer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Pfizer: Product Benchmarking
Table 97 Pfizer: Strategic Outlook
Table 98 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Novartis AG: Product Benchmarking
Table 100 Novartis AG: Strategic Outlook
Table 101 UCB S.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 UCB S.A.: Product Benchmarking
Table 103 UCB S.A.: Strategic Outlook
Table 104 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Biogen: Product Benchmarking
Table 106 Biogen: Strategic Outlook
Table 107 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 F. Hoffmann-La Roche Ltd: Product Benchmarking
Table 109 Celltrion Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Celltrion Corporation: Product Benchmarking
Table 111 Celltrion Corporation: Strategic Outlook
Table 112 Ferring B.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Ferring B.V.: Product Benchmarking
Table 114 Ferring B.V.: Strategic Outlook

List of Figures
Figure 1 Inflammatory Bowel Diseases Drugs Market Segmentation
Figure 2 Inflammatory Bowel Diseases Drugs Market by Indication: Market Attractiveness Index
Figure 3 Inflammatory Bowel Diseases Drugs Market by Route of Administration: Market Attractiveness Index
Figure 4 Inflammatory Bowel Diseases Drugs Market by Distribution Channel: Market Attractiveness Index
Figure 5 Inflammatory Bowel Diseases Drugs Market by Drug Class: Market Attractiveness Index
Figure 6 Inflammatory Bowel Diseases Drugs Market by Drugs: Market Attractiveness Index
Figure 7 Inflammatory Bowel Diseases Drugs Market Attractiveness Index by Region
Figure 8 Inflammatory Bowel Diseases Drugs Market: Market Dynamics
Figure 9 Inflammatory Bowel Diseases Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “V” Shaped Recovery
Figure 10 Inflammatory Bowel Diseases Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “U” Shaped Recovery
Figure 11 Inflammatory Bowel Diseases Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “W” Shaped Recovery
Figure 12 Inflammatory Bowel Diseases Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “L” Shaped Recovery
Figure 13 Inflammatory Bowel Diseases Drugs Market: Porter’s Five Forces Analysis
Figure 14 IBD Drugs Market: PEST Analysis
Figure 15 Inflammatory Bowel Diseases Drugs Market by Indication: Market Attractiveness Index
Figure 16 Inflammatory Bowel Diseases Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 17 Inflammatory Bowel Diseases Drugs Market Share Forecast by Indication, 2024, 2029, 2034 (%)
Figure 18 Crohn’s Disease Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 19 Crohn’s Disease Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 20 Ulcerative Colitis Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 21 Ulcerative Colitis Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 22 Inflammatory Bowel Diseases Drugs Market by Route of Administration: Market Attractiveness Index
Figure 23 Inflammatory Bowel Diseases Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 24 Inflammatory Bowel Diseases Drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 25 Oral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 26 Oral Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 27 Parental Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 28 Parenteral Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Rectal Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 30 Rectal Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 Inflammatory Bowel Diseases Drugs Market by Distribution Channel: Market Attractiveness Index
Figure 32 Inflammatory Bowel Diseases Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 33 Inflammatory Bowel Diseases Drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 34 Hospital Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 35 Hospital Pharmacy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 36 Retail Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 37 Retail Pharmacy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 38 E-commerce Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 39 E-commerce Pharmacy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 40 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 41 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 42 Inflammatory Bowel Diseases Drugs Market by Drug Class: Market Attractiveness Index
Figure 43 Inflammatory Bowel Diseases Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 44 Inflammatory Bowel Diseases Drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 45 TNF-alpha Blockers Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 46 TNF-alpha Blockers Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 47 Integrin Blockers Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 48 Integrin Blockers Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 49 Interleukin Inhibitors Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 50 Interleukin Inhibitors Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 51 JAK inhibitors Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 52 JAK inhibitors Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 53 S1Ps Modulators and Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 54 S1Ps Modulators and Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 55 Inflammatory Bowel Diseases Drugs Market by Drugs: Market Attractiveness Index
Figure 56 Inflammatory Bowel Diseases Drugs Market Forecast by Drugs, 2024-2034 (US$ Billion, AGR %)
Figure 57 Inflammatory Bowel Diseases Drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 58 Cimzia Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 59 Cimzia Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 60 Entyvio Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 61 Entyvio Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 62 Humira Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 63 Humira Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 64 Rinvoq Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 65 Rinvoq Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 66 Skyrizi Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 67 Skyrizi Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 68 Remicade Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 69 Remicade Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 70 Simponi Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 71 Simponi Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 72 Stelara Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 73 Stelara Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 74 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 75 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 76 Inflammatory Bowel Diseases Drugs Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 77 Inflammatory Bowel Diseases Drugs Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 78 Inflammatory Bowel Diseases Drugs Market by Region, 2024-2034 (US$ Billion, AGR %)
Figure 79 North America Inflammatory Bowel Diseases Drugs Market Attractiveness Index
Figure 80 North America Inflammatory Bowel Diseases Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 81 North America Inflammatory Bowel Diseases Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 82 North America Inflammatory Bowel Diseases Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 83 North America Inflammatory Bowel Diseases Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 84 North America Inflammatory Bowel Diseases Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 85 North America Inflammatory Bowel Diseases Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 86 North America Inflammatory Bowel Diseases Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 87 North America Inflammatory Bowel Diseases Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 88 North America Inflammatory Bowel Diseases Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 89 North America Inflammatory Bowel Diseases Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 90 North America Inflammatory Bowel Diseases Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 91 North America Inflammatory Bowel Diseases Drugs Market Forecast by Drugs, 2024-2034 (US$ Billion, AGR %)
Figure 92 North America Inflammatory Bowel Diseases Drugs Market Share Forecast by Drugs, 2024 & 2034 (%)
Figure 93 U.S. Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 94 Canada Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 95 Europe Inflammatory Bowel Diseases Drugs Market Attractiveness Index
Figure 96 Europe Inflammatory Bowel Diseases Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 97 Europe Inflammatory Bowel Diseases Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 98 Europe Inflammatory Bowel Diseases Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 99 Europe Inflammatory Bowel Diseases Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 100 Europe Inflammatory Bowel Diseases Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 101 Europe Inflammatory Bowel Diseases Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 102 Europe Inflammatory Bowel Diseases Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 103 Europe Inflammatory Bowel Diseases Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 104 Europe Inflammatory Bowel Diseases Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 105 Europe Inflammatory Bowel Diseases Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 106 Europe Inflammatory Bowel Diseases Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 107 Europe Inflammatory Bowel Diseases Drugs Market Forecast by Drugs, 2024-2034 (US$ Billion, AGR %)
Figure 108 Europe Inflammatory Bowel Diseases Drugs Market Share Forecast by Drugs, 2024 & 2034 (%)
Figure 109 Germany Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 110 France Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 111 UK Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 112 Italy Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 113 Spain Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 114 Rest of Europe Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 115 Asia Pacific Inflammatory Bowel Diseases Drugs Market Attractiveness Index
Figure 116 Asia Pacific Inflammatory Bowel Diseases Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 117 Asia Pacific Inflammatory Bowel Diseases Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 118 Asia Pacific Inflammatory Bowel Diseases Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 119 Asia Pacific Inflammatory Bowel Diseases Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 120 Asia Pacific Inflammatory Bowel Diseases Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 121 Asia Pacific Inflammatory Bowel Diseases Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 122 Asia Pacific Inflammatory Bowel Diseases Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 123 Asia Pacific Inflammatory Bowel Diseases Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 124 Asia Pacific Inflammatory Bowel Diseases Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 125 Asia Pacific Inflammatory Bowel Diseases Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 126 Asia Pacific Inflammatory Bowel Diseases Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 127 Asia Pacific Inflammatory Bowel Diseases Drugs Market Forecast by Drugs, 2024-2034 (US$ Billion, AGR %)
Figure 128 Asia Pacific Inflammatory Bowel Diseases Drugs Market Share Forecast by Drugs, 2024 & 2034 (%)
Figure 129 Japan Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 130 China Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 131 India Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 132 Australia Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 133 South Korea Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 134 Rest of Asia Pacific Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 135 Latin America Inflammatory Bowel Diseases Drugs Market Attractiveness Index
Figure 136 Latin America Inflammatory Bowel Diseases Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 137 Latin America Inflammatory Bowel Diseases Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 138 Latin America Inflammatory Bowel Diseases Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 139 Latin America Inflammatory Bowel Diseases Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 140 Latin America Inflammatory Bowel Diseases Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 141 Latin America Inflammatory Bowel Diseases Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 142 Latin America Inflammatory Bowel Diseases Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 143 Latin America Inflammatory Bowel Diseases Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 144 Latin America Inflammatory Bowel Diseases Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 145 Latin America Inflammatory Bowel Diseases Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 146 Latin America Inflammatory Bowel Diseases Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 147 Latin America Inflammatory Bowel Diseases Drugs Market Forecast by Drugs, 2024-2034 (US$ Billion, AGR %)
Figure 148 Latin America Inflammatory Bowel Diseases Drugs Market Share Forecast by Drugs, 2024 & 2034 (%)
Figure 149 Brazil Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 150 Mexico Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 151 Rest of Latin America Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 152 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Attractiveness Index
Figure 153 Middle East and Africa Inflammatory Bowel Diseases Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 154 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 155 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 156 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 157 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 158 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 159 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 160 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 161 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 162 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 163 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 164 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Forecast by Drugs, 2024-2034 (US$ Billion, AGR %)
Figure 165 Middle East and Africa Inflammatory Bowel Diseases Drugs Market Share Forecast by Drugs, 2024 & 2034 (%)
Figure 166 GCC Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 167 South Africa Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 168 Rest of MEA Inflammatory Bowel Diseases Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 169 Inflammatory Bowel Diseases Drugs Market: Company Share/Ranking, 2023
Figure 170 AbbVie: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 171 AbbVie: R&D, 2018-2022 (US$ Million, AGR%)
Figure 172 AbbVie: Regional Market Shares, 2022
Figure 173 Johnson & Johnson Private Limited: Annual Revenue, 2018-2022 (US$ Million, AGR%)
Figure 174 Johnson & Johnson Private Limited: Regional Market Shares, 2022
Figure 175 Takeda Pharmaceutical Company Limited: Net Revenue, 2019-2023 (US$ Billion, AGR%)
Figure 176 Takeda Pharmaceutical Company Limited: R&D, 2019-2023 (US$ Billion, AGR%)
Figure 177 Takeda Pharmaceutical Company Limited: Regional Market Shares, 2022
Figure 178 Pfizer: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 179 Pfizer: R&D, 2018-2022 (US$ Million, AGR%)
Figure 180 Pfizer: Regional Market Shares, 2022
Figure 181 Novartis AG: Net Revenue, 2018-2022 (US$ Billion, AGR%)
Figure 182 Novartis AG: R&D, 2018-2022 (US$ Billion, AGR%)
Figure 183 Novartis AG: Regional Market Shares, 2022
Figure 184 UCB S.A.: Net Revenue, 2019-20233 (US$ Billion, AGR%)
Figure 185 UCB S.A.: R&D, 2019-2023 (US$ Billion, AGR%)
Figure 186 UCB S.A.: Regional Market Shares, 2023
Figure 187 Biogen: Net Revenue, 2019-2023 (US$ Billion, AGR%)
Figure 188 Biogen: R&D, 2019-2023 (US$ Billion, AGR%)
Figure 189 F. Hoffmann-La Roche Ltd: Net Revenue, 2018-2022 (US$ Billion, AGR%)
Figure 190 F. Hoffmann-La Roche Ltd: R&D Expense, 2018-2022 (US$ Billion, AGR%)
Figure 191 Celltrion Corporation: Net Revenue, 2018-2022 (US$ Billion, AGR%)
Figure 192 Celltrion Corporation: R&D, 2018-2022 (US$ Billion, AGR%)

この商品のレポートナンバー

0000038047

TOP